metformin has been researched along with Ventricular Dysfunction, Left in 25 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin treatment is associated with improved outcome after myocardial infarction in patients with diabetes." | 9.19 | Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. ( de Boer, RA; de Smet, BJ; Dorhout, B; Hillege, HL; Lexis, CP; Lipsic, E; Molmans, BH; Nieuwland, W; Pundziute, G; Schurer, RA; Tan, ES; ter Horst, GJ; Tijssen, JG; van den Heuvel, AF; van der Harst, P; van der Horst, IC; van der Horst-Schrivers, AN; van der Werf, HW; van Rossum, AC; van Veldhuisen, DJ; Wieringa, WG; Willemsen, HM; Wolffenbuttel, BH, 2014) |
| "There is an ongoing controversy regarding the safety and effectiveness of metformin in the setting of heart failure (HF)." | 8.89 | Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. ( Eurich, DT; Johnson, JA; Majumdar, SR; McAlister, FA; Tjosvold, L; Tsuyuki, RT; Vanderloo, SE; Weir, DL, 2013) |
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 8.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK)." | 7.80 | Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. ( Clanachan, AS; Garjani, A; Ghazi-Khansari, M; Maleki-Dizaji, N; Rameshrad, M; Soraya, H, 2014) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 7.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| "Metformin treatment is associated with improved outcome after myocardial infarction in patients with diabetes." | 5.19 | Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. ( de Boer, RA; de Smet, BJ; Dorhout, B; Hillege, HL; Lexis, CP; Lipsic, E; Molmans, BH; Nieuwland, W; Pundziute, G; Schurer, RA; Tan, ES; ter Horst, GJ; Tijssen, JG; van den Heuvel, AF; van der Harst, P; van der Horst, IC; van der Horst-Schrivers, AN; van der Werf, HW; van Rossum, AC; van Veldhuisen, DJ; Wieringa, WG; Willemsen, HM; Wolffenbuttel, BH, 2014) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "There is an ongoing controversy regarding the safety and effectiveness of metformin in the setting of heart failure (HF)." | 4.89 | Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. ( Eurich, DT; Johnson, JA; Majumdar, SR; McAlister, FA; Tjosvold, L; Tsuyuki, RT; Vanderloo, SE; Weir, DL, 2013) |
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 4.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| " What is the main finding and its importance? We demonstrated, for the first time, that DPP-4 inhibitor, but not metformin, exerted similar efficacy in improving cardiac function and attenuating cardiac fibrosis compared with enalapril in rats with chronic MI." | 3.81 | Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W, 2015) |
| "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK)." | 3.80 | Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. ( Clanachan, AS; Garjani, A; Ghazi-Khansari, M; Maleki-Dizaji, N; Rameshrad, M; Soraya, H, 2014) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 3.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| "In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective." | 3.73 | Determinants of subclinical diabetic heart disease. ( Downey, M; Fang, ZY; Marwick, TH; Prins, J; Schull-Meade, R, 2005) |
| "Metformin treatment improved diastolic function in animal models and patients with diabetes." | 2.82 | The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. ( Al Ali, L; Hartman, MT; Hummel, YM; Lexis, CP; Lipsic, E; van der Harst, P; van der Horst, IC; van Melle, JP; van Veldhuisen, DJ; Voors, AA, 2016) |
| "Treatment with metformin reduced peripheral metabolic impairment and cardiac dysfunction via decreased cardiac mitochondrial dysfunction, mitochondrial dynamic imbalance, and apoptosis." | 1.62 | Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jinawong, K; Kerdphoo, S; Singhanat, K, 2021) |
| "Metformin intervention was used to further evaluate potential therapeutic amelioration of cardiac dysfunction in this model." | 1.51 | Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease. ( Archer, SK; Bais, P; Cagnone, G; Chandran, A; Coleman, D; Costa, MW; Forte, E; Furtado, MB; Heineke, J; Hon, O; Kocalis, H; Pandey, R; Patel, HH; Pearson, JT; Philip, V; Ramialison, M; Rosenthal, NA; Schilling, JM; Wilmanns, JC; Wu, Q, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, A | 1 |
| Node, K | 1 |
| Khan, MS | 1 |
| DeVore, AD | 1 |
| Felker, GM | 1 |
| Butler, J | 1 |
| Fonarow, GC | 1 |
| Greene, SJ | 1 |
| Arinno, A | 2 |
| Maneechote, C | 2 |
| Khuanjing, T | 2 |
| Prathumsap, N | 2 |
| Chunchai, T | 2 |
| Arunsak, B | 2 |
| Nawara, W | 2 |
| Kerdphoo, S | 3 |
| Shinlapawittayatorn, K | 2 |
| Chattipakorn, SC | 4 |
| Chattipakorn, N | 5 |
| Jo, W | 1 |
| Kang, KK | 1 |
| Chae, S | 1 |
| Son, WC | 1 |
| Apaijai, N | 3 |
| Jinawong, K | 1 |
| Singhanat, K | 1 |
| Jaiwongkam, T | 1 |
| Topal, AE | 1 |
| Kelle, I | 1 |
| Akkoc, H | 1 |
| Yilmaz, S | 2 |
| Akkus, M | 1 |
| Ghandi, Y | 1 |
| Habibi, D | 1 |
| Nasri, K | 1 |
| Alinejad, S | 1 |
| Taherahmad, H | 1 |
| Arjmand Shabestari, A | 1 |
| Nematinejad, A | 1 |
| Wilmanns, JC | 1 |
| Pandey, R | 1 |
| Hon, O | 1 |
| Chandran, A | 1 |
| Schilling, JM | 1 |
| Forte, E | 1 |
| Wu, Q | 1 |
| Cagnone, G | 1 |
| Bais, P | 1 |
| Philip, V | 1 |
| Coleman, D | 1 |
| Kocalis, H | 1 |
| Archer, SK | 1 |
| Pearson, JT | 1 |
| Ramialison, M | 1 |
| Heineke, J | 1 |
| Patel, HH | 1 |
| Rosenthal, NA | 1 |
| Furtado, MB | 1 |
| Costa, MW | 1 |
| Hendriks, T | 1 |
| Al Ali, L | 2 |
| Maagdenberg, CG | 1 |
| van Melle, JP | 2 |
| Hummel, YM | 2 |
| Oudkerk, M | 1 |
| van Veldhuisen, DJ | 5 |
| Nijveldt, R | 1 |
| van der Horst, ICC | 1 |
| Lipsic, E | 5 |
| van der Harst, P | 5 |
| Eurich, DT | 1 |
| Weir, DL | 1 |
| Majumdar, SR | 1 |
| Tsuyuki, RT | 1 |
| Johnson, JA | 1 |
| Tjosvold, L | 1 |
| Vanderloo, SE | 1 |
| McAlister, FA | 1 |
| Ladeiras-Lopes, R | 1 |
| Fontes-Carvalho, R | 1 |
| Bettencourt, N | 1 |
| Sampaio, F | 1 |
| Gama, V | 1 |
| Leite-Moreira, AF | 1 |
| Lexis, CP | 4 |
| van der Horst, IC | 4 |
| Wieringa, WG | 1 |
| de Boer, RA | 2 |
| van den Heuvel, AF | 1 |
| van der Werf, HW | 1 |
| Schurer, RA | 1 |
| Pundziute, G | 1 |
| Tan, ES | 1 |
| Nieuwland, W | 1 |
| Willemsen, HM | 1 |
| Dorhout, B | 1 |
| Molmans, BH | 1 |
| van der Horst-Schrivers, AN | 2 |
| Wolffenbuttel, BH | 2 |
| ter Horst, GJ | 1 |
| van Rossum, AC | 2 |
| Tijssen, JG | 1 |
| Hillege, HL | 1 |
| de Smet, BJ | 2 |
| Mearns, BM | 1 |
| Soraya, H | 1 |
| Clanachan, AS | 1 |
| Rameshrad, M | 1 |
| Maleki-Dizaji, N | 1 |
| Ghazi-Khansari, M | 1 |
| Garjani, A | 1 |
| Chinda, K | 1 |
| Palee, S | 1 |
| Chattipakorn, S | 1 |
| Caffrey, MK | 1 |
| Inthachai, T | 1 |
| Lekawanvijit, S | 1 |
| Kumfu, S | 1 |
| Pongkan, W | 1 |
| Haver, VG | 1 |
| Hartman, MH | 1 |
| Mateo Leach, I | 1 |
| van Gilst, WH | 1 |
| Paneni, F | 1 |
| Costantino, S | 1 |
| Cosentino, F | 1 |
| Hartman, MT | 1 |
| Voors, AA | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Sasaki, H | 1 |
| Asanuma, H | 1 |
| Fujita, M | 1 |
| Takahama, H | 1 |
| Wakeno, M | 1 |
| Ito, S | 1 |
| Ogai, A | 1 |
| Asakura, M | 1 |
| Kim, J | 1 |
| Minamino, T | 1 |
| Takashima, S | 1 |
| Sanada, S | 1 |
| Sugimachi, M | 1 |
| Komamura, K | 1 |
| Mochizuki, N | 1 |
| Kitakaze, M | 1 |
| Fang, ZY | 1 |
| Schull-Meade, R | 1 |
| Downey, M | 1 |
| Prins, J | 1 |
| Marwick, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.[NCT01217307] | Phase 2/Phase 3 | 380 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months. (NCT01217307)
Timeframe: 4 months
| Intervention | % of LVEF (Mean) |
|---|---|
| Metformin | 53.1 |
| Placebo | 54.8 |
2 reviews available for metformin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.
Topics: Comorbidity; Comparative Effectiveness Research; Contraindications; Diabetic Angiopathies; Heart Fai | 2013 |
[Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications].
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Myocardial Reperfu | 2015 |
7 trials available for metformin and Ventricular Dysfunction, Left
16 other studies available for metformin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Metformin; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function | 2022 |
Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction.
Topics: Heart Failure; Humans; Metformin; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function | 2022 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Metformin Alleviates Left Ventricular Diastolic Dysfunction in a Rat Myocardial Ischemia Reperfusion Injury Model.
Topics: Animals; Disease Models, Animal; Echocardiography; Gene Expression Profiling; Gene Expression Regula | 2020 |
Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats.
Topics: Animals; Diet, High-Fat; Imidazoles; Indoles; Insulin Resistance; Male; Metformin; Mitochondria, Hea | 2021 |
Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Male; Metformin; Myocardium; Non-alcoholic F | 2017 |
Effect of well-controlled gestational diabetes on left ventricular diastolic dysfunction in neonates.
Topics: Adult; Cardiomegaly; Case-Control Studies; Cross-Sectional Studies; Diabetes, Gestational; Echocardi | 2019 |
Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease.
Topics: Animals; Cardiac Output; Energy Metabolism; Heart Defects, Congenital; Hypoglycemic Agents; Male; Me | 2019 |
Acute coronary syndromes: Metformin not associated with improved left ventricular function after STEMI in patients without diabetes mellitus.
Topics: Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Ventricular Dysfunction | 2014 |
Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
Topics: AMP-Activated Protein Kinases; Animals; Hemodynamics; Interleukin-6; Isoproterenol; Male; Metformin; | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
Study answers long-standing question about metformin after heart attack.
Topics: Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Ventricular Dysfunction | 2014 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Pe | 2015 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; C | 2009 |
Determinants of subclinical diabetic heart disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Body Mass Index; Diabetes Complicati | 2005 |